Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals.

Competing Interests: This work was supported in part by the Japan Agency for Medical Research and Development (AMED) Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA) Japan Initiative for World-leading Vaccine Research and Development Centers UTOPIA programme (JP223fa627001 to KSa), AMED SCARDA Program on R&D of New Generation Vaccine Including New Modality Application (JP223fa727002 to KSa); AMED Research Program on Emerging and Re-emerging Infectious Diseases (JP22fk0108146 to KSa; JP21fk0108494 to G2P-Japan Consortium and KSa; JP21fk0108425 to KSa; JP21fk0108432 to KSa; JP22fk0108511 to G2P-Japan Consortium and KSa; JP22fk0108516 to KSa; JP22fk0108506 to KSa; JP22fk0108534 to KSa); AMED Research Program on HIV/AIDS (JP22fk0410039 to KSa); Japan Science and Technology Agency (JST) Core Research for Evolutional Science and Technology (CREST; JPMJCR20H4 to KSa); Japan Society for the Promotion of Science (JSPS) KAKENHI Fund for the Promotion of Joint International Research (International Leading Research) (JP23K20041 to G2P-Japan and KSa); JSPS Core-to-Core Program (A Advanced Research Networks; JPJSCCA20190008 to KSa); JSPS Research Fellow DC2 (22J11578 to KU); JSPS Research Fellow DC1 (23KJ0710 to YKo); The Tokyo Biochemical Research Foundation (to KSa); and The Mitsubishi Foundation (to KSa). KSa has received consulting fees from Moderna Japan and Takeda Pharmaceutical and honoraria for lectures from Gilead Sciences, Moderna Japan, and Shionogi & Co. All other authors declare no competing interests. Members of The Genotype to Phenotype Japan (G2P-Japan) Consortium are listed in the appendix (p 9).